Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.

CONCLUSION: This study highlights the promise of a blood-based, sequencing minimal-residual-disease assay that can be used to measure MM disease burden at different time points and various disease stages.
PMID: 24629890 [PubMed - in process]

Source: Clinical Lymphoma and Myeloma - March 22, 2014 Category: Cancer & Oncology Authors: Vij R, Mazumder A, Klinger M, O'Dea D, Paasch J, Martin T, Weng L, Park J, Fiala M, Faham M, Wolf J Tags: Clin Lymphoma Myeloma Leuk Source Type: research